Jerry S. Lanchbury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jerry S. Lanchbury has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Gutin
Myriad Genetics, Inc., Salt Lake City, UT
10 shared publications - Elisha Hughes
Myriad Genetics, Inc, Salt Lake City, UT
9 shared publications - Ryan Bernhisel
Myriad Genetics, Inc., Salt Lake City, UT
9 shared publications - Susanne Wagner
Myriad Genetics, Inc., Salt Lake City, UT
9 shared publications - Anastasia Constantinidou
Medical School, University of Cyprus, Nicosia, Cyprus
8 shared publications - Braden Probst
Myriad Genetics, Inc, Salt Lake City, UT
8 shared publications
Latest Publications
- Open Access
Within- and Between-Family Validation of Nine Polygenic Risk Scores Developed in 1.5 Million Individuals: Implications for IVF, Embryo Selection, and Reduction in Lifetime Disease Risk
Polygenic risk scores (PRSs) can reduce lifetime disease risk by guiding embryo selection during in vitro fertilization (IVF). We performed genome-wide association meta-analyses totaling ∼1.5 million individuals to construct state-of-the-art PRSs for nine diseases: Alzheimer’s disease, breast cancer, coronary artery disease, endometriosis, hypertension, prostate cancer, rheumatoid arthritis, type 1 diabetes, and type 2 diabetes. The resulting predictors achieved liability-scale R 2 values of up to 22.9% for type 2 diabetes, matching or exceeding previously published benchmarks across all scores. Three PRS - Alzheimer’s disease, prostate cancer, and type 2 diabetes - explained over 75% of the common-SNP heritability. Within-family validation in 40,872 siblings across 18,840 families showed that, for eight of nine diseases, predictive performance was comparable to population-level results, confirming substantial direct genetic effects. Modeling of embryo selection suggests that couples with five euploid embryos could achieve 27-67% relative risk reduction across diseases. While the limitations of genetic data availability meant that these estimates were performed in European ancestry samples, we performed validation in the multi-ancestry US-based All of Us Biobank, demonstrating significant statistical power across ancestries. These findings support the clinical applicability of PRS-guided embryo selection to reduce the burden of common diseases.
Open AccessWithin- and Between-Family Validation of Nine Polygenic Risk Scores Developed in 1.5 Million Individuals: Implications for IVF, Embryo Selection, and Reduction in Lifetime Disease Risk
Polygenic risk scores (PRSs) can reduce lifetime disease risk by guiding embryo selection during in vitro fertilization (IVF). We performed genome-wide association meta-analyses totaling ∼1.5 million individuals to construct state-of-the-art PRSs for nine diseases: Alzheimer’s disease, breast cancer, coronary artery disease, endometriosis, hypertension, prostate cancer, rheumatoid arthritis, type 1 diabetes, and type 2 diabetes. The resulting predictors achieved liability-scale R 2 values of up to 22.9% for type 2 diabetes, matching or exceeding previously published benchmarks across all scores. Three PRS - Alzheimer’s disease, prostate cancer, and type 2 diabetes - explained over 75% of the common-SNP heritability. Within-family validation in 40,872 siblings across 18,840 families showed that, for eight of nine diseases, predictive performance was comparable to population-level results, confirming substantial direct genetic effects. Modeling of embryo selection suggests that couples with five euploid embryos could achieve 27-67% relative risk reduction across diseases. While the limitations of genetic data availability meant that these estimates were performed in European ancestry samples, we performed validation in the multi-ancestry US-based All of Us Biobank, demonstrating significant statistical power across ancestries. These findings support the clinical applicability of PRS-guided embryo selection to reduce the burden of common diseases.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose:The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women.Experimental Design:Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis.Results:After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively.Conclusions:The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose:The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women.Experimental Design:Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis.Results:After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively.Conclusions:The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose:The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women.Experimental Design:Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis.Results:After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively.Conclusions:The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose:The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women.Experimental Design:Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis.Results:After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively.Conclusions:The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Figure from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
- Open Access
- 31 August 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (20) , 4435-4443
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose: The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Experimental Design: Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis. Results: After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively. Conclusions: The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- 31 August 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (20) , 4435-4443
Open AccessClinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Purpose: The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor–positive (ER+), HER2− breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Experimental Design: Tumor samples from 385 pre-menopausal women with ER+, HER2− primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy were tested with EndoPredict to produce a 12-gene EP molecular score and an integrated EPclin score that includes pathologic tumor size and nodal status. Associations of molecular and EPclin scores with 10-year distant recurrence–free survival (DRFS) were evaluated by Cox proportional hazards models and Kaplan–Meier analysis. Results: After a median follow-up of 9.7 years, both the EP molecular score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR, 1.33; 95% confidence interval (CI), 1.18–1.50; P = 7.2 × 10–6; HR, 3.58; 95% CI, 2.26–5.66; P = 9.8 × 10–8, respectively]. Both scores remained significant after adjusting for clinical factors in multivariate analysis. Patients with low-risk EPclin scores (64.7%) had significantly improved DRFS compared with high-risk patients (HR, 4.61; 95% CI, 1.40–15.17; P = 4.2 × 10–3). At 10 years, patients with low-risk and high-risk EPclin scores had a DRFS of 97% (95% CI, 93%–99%) and 76% (95% CI, 67%–82%), respectively. Conclusions: The EPclin score is strongly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. On the basis of these data, pre-menopausal women with EPclin low-risk breast cancer may be treated with endocrine therapy only and safely forgo adjuvant chemotherapy.
- Open Access
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P2-11
Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model
Background: Polygenic risk scores (PRS) have been shown to provide genomically informed breast cancer risk assessment in both carriers and non-carriers of predisposing genetic mutations. Risk stratification is further improved by combining a PRS with risk models incorporating traditional risk factors to generate a Combined Risk Score (CRS). We recently developed and validated a breast cancer PRS for women of diverse ancestries using ancestry-informative genetic markers. Here, we combine the diverse ancestry PRS with a clinical and family history-based model to develop an integrated genomically-informed and ancestrally unbiased risk assessment tool. Methods: The study sample included women in the U.S. without a personal history of breast cancer, referred for clinical genetic testing between June 2020 and March 2021, and who tested negative for pathogenic or likely pathogenic variants in breast cancer susceptibility genes. A CRS, incorporating a validated PRS and the TC model, was generated using a previously described Fixed-Stratified method that accounts for association between PRS and clinical risk factors. Association between the PRS and each clinical risk factor included in the Tyrer-Cuzick (TC) breast cancer risk model (version 7) was tested using linear regression with PRS as the dependent variable and the TC factor as an independent variable with adjustment for age and ancestry. We examined the rate of reclassification resulting from incorporation of PRS into the CRS by classifying women as having high (>20%) remaining lifetime risk (RLR) versus low (≤20%) RLR according to both TC and CRS. Results: Among 68,803 women, 21,500 (31.2%) had one or more first degree relatives (FDR) with breast cancer. Approximately 10% of women reported only African ancestry and a similar percentage reported only Hispanic/Latina ethnicity (Table 1). Family history was significantly associated with PRS (p=1.0x10-76). After adjusting for multiple testing, no other factors showed significant association with PRS. Improved risk stratification of CRS over TC follows from two results: (1) We previously showed that PRS improved risk stratification above and beyond family history; (2) In the present study, PRS was not associated with any TC factor other than family history. Adding the PRS to the TC model significantly altered breast cancer risk estimates for women of all ancestries, with 17.3% of patients stratified differently by CRS versus TC alone. Differences in risk stratification (using the 20% threshold) for each self-reported ancestry are presented in Table 1. The CRS classified fewer patients (32.0%) as high RLR than the TC model alone (35.4%), with similar results for 5-year risk estimates. Conclusions: This is the first genomically-informed, integrated polygenic and traditional breast cancer risk model for US women referred for contemporary clinical genetic testing. This model advances the PRS component of a previously validated combined model. It effectively estimates 5-year and lifetime risk for breast cancer using a PRS with an objectively genetically determined ancestral composition, calibrated and validated for risk stratification in all ancestries. The model may reliably and responsibly inform risk reduction strategies such as enhanced surveillance and use of preventive medications. Citation Format: Elisha Hughes, Ryan Bernhisel, Holly Pederson, Braden Probst, Timothy Simmons, Susanne Wagner, Thaddeus Judkins, Eric Rosenthal, Benjamin Roa, Susan M. Domchek, Charis Eng, Judy Garber, Monique Gary, Ora K. Gordon, Jennifer Klemp, Semanti Mukherjee, Kenneth Offit, Funmi Olopade, Joseph Vijai, Jeffrey N. Weitzel, Pat Whitworth, Lamis Yehia, Allison Kurian, Mark Robson, Thomas P. Slavin, Alexander Gutin, Jerry S. Lanchbury. Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-11-21.
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P2-11
Open AccessAbstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model
Background: Polygenic risk scores (PRS) have been shown to provide genomically informed breast cancer risk assessment in both carriers and non-carriers of predisposing genetic mutations. Risk stratification is further improved by combining a PRS with risk models incorporating traditional risk factors to generate a Combined Risk Score (CRS). We recently developed and validated a breast cancer PRS for women of diverse ancestries using ancestry-informative genetic markers. Here, we combine the diverse ancestry PRS with a clinical and family history-based model to develop an integrated genomically-informed and ancestrally unbiased risk assessment tool. Methods: The study sample included women in the U.S. without a personal history of breast cancer, referred for clinical genetic testing between June 2020 and March 2021, and who tested negative for pathogenic or likely pathogenic variants in breast cancer susceptibility genes. A CRS, incorporating a validated PRS and the TC model, was generated using a previously described Fixed-Stratified method that accounts for association between PRS and clinical risk factors. Association between the PRS and each clinical risk factor included in the Tyrer-Cuzick (TC) breast cancer risk model (version 7) was tested using linear regression with PRS as the dependent variable and the TC factor as an independent variable with adjustment for age and ancestry. We examined the rate of reclassification resulting from incorporation of PRS into the CRS by classifying women as having high (>20%) remaining lifetime risk (RLR) versus low (≤20%) RLR according to both TC and CRS. Results: Among 68,803 women, 21,500 (31.2%) had one or more first degree relatives (FDR) with breast cancer. Approximately 10% of women reported only African ancestry and a similar percentage reported only Hispanic/Latina ethnicity (Table 1). Family history was significantly associated with PRS (p=1.0x10-76). After adjusting for multiple testing, no other factors showed significant association with PRS. Improved risk stratification of CRS over TC follows from two results: (1) We previously showed that PRS improved risk stratification above and beyond family history; (2) In the present study, PRS was not associated with any TC factor other than family history. Adding the PRS to the TC model significantly altered breast cancer risk estimates for women of all ancestries, with 17.3% of patients stratified differently by CRS versus TC alone. Differences in risk stratification (using the 20% threshold) for each self-reported ancestry are presented in Table 1. The CRS classified fewer patients (32.0%) as high RLR than the TC model alone (35.4%), with similar results for 5-year risk estimates. Conclusions: This is the first genomically-informed, integrated polygenic and traditional breast cancer risk model for US women referred for contemporary clinical genetic testing. This model advances the PRS component of a previously validated combined model. It effectively estimates 5-year and lifetime risk for breast cancer using a PRS with an objectively genetically determined ancestral composition, calibrated and validated for risk stratification in all ancestries. The model may reliably and responsibly inform risk reduction strategies such as enhanced surveillance and use of preventive medications. Citation Format: Elisha Hughes, Ryan Bernhisel, Holly Pederson, Braden Probst, Timothy Simmons, Susanne Wagner, Thaddeus Judkins, Eric Rosenthal, Benjamin Roa, Susan M. Domchek, Charis Eng, Judy Garber, Monique Gary, Ora K. Gordon, Jennifer Klemp, Semanti Mukherjee, Kenneth Offit, Funmi Olopade, Joseph Vijai, Jeffrey N. Weitzel, Pat Whitworth, Lamis Yehia, Allison Kurian, Mark Robson, Thomas P. Slavin, Alexander Gutin, Jerry S. Lanchbury. Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-11-21.
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 537
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
537 Background: The EndoPredict 12-gene prognostic assay is validated to predict distant recurrence-free survival (DRFS) and response to chemotherapy in post-menopausal women with ER+, HER2- breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Methods: Stored tumor samples from women with ER+, HER2- primary breast cancer who were pre-menopausal at the time of diagnosis and were systemically treated with endocrine therapy alone were obtained from two sites (University of Nottingham and University of Cyprus). These samples were tested with EndoPredict to produce a 12-gene molecular score (EP). Pathologic tumor size and nodal status were algorithmically combined with the EP score to produce the clinicomolecular EPclin score. Cases with tumors > pT3, which were treated with chemotherapy, or for whom the EPclin score was missing or invalid were excluded. Associations of EP and EPclin with 10-year DRFS were evaluated in terms of hazard ratios (HRs) from Cox proportional hazards models stratified by cohort. 10-year DRFS was estimated for EPclin high-risk and low-risk women by Kaplan-Meier analysis. Results: Out of 411 eligible cases, 385 had a valid EPclin score and were included in the analysis. Mean age at breast cancer diagnosis was 46.5 years (standard deviation 4.7). Most women (N = 239, 62.6%) had grade II tumors and 16.1% (N = 62) had node-positive disease. Over the observation period (median 9.7 years, interquartile range 6.6-13.9 years), 35 women had a distant recurrence within 10 years. Both the molecular EP score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR 1.3, 95% confidence interval (CI) 1.2-1.5; p < 0.001 and HR 3.6, 95% CI 2.3-5.7; p < 0.001, respectively]. Of these patients, 249 (64.7%) were categorized as low risk by EPclin score while the remaining 136 (35.3%) were categorized as high risk. Compared to EPclin low-risk women, EPclin high-risk patients were more likely to experience distant recurrence (HR 4.6, 95% CI 1.4-15.2; p = 0.004). At 10 years post-diagnosis, EPclin low-risk women who received endocrine therapy alone had a DRFS of 97% (95% CI 93-99%). Conversely, EPclin high-risk women had a DRFS of only 76% (95% CI 67-82%). Conclusions: The EPclin score is highly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. Based on these data, pre-menopausal women with EPclin low-risk breast cancer may safely forgo adjuvant chemotherapy in addition to endocrine therapy.
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 537
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
537 Background: The EndoPredict 12-gene prognostic assay is validated to predict distant recurrence-free survival (DRFS) and response to chemotherapy in post-menopausal women with ER+, HER2- breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Methods: Stored tumor samples from women with ER+, HER2- primary breast cancer who were pre-menopausal at the time of diagnosis and were systemically treated with endocrine therapy alone were obtained from two sites (University of Nottingham and University of Cyprus). These samples were tested with EndoPredict to produce a 12-gene molecular score (EP). Pathologic tumor size and nodal status were algorithmically combined with the EP score to produce the clinicomolecular EPclin score. Cases with tumors > pT3, which were treated with chemotherapy, or for whom the EPclin score was missing or invalid were excluded. Associations of EP and EPclin with 10-year DRFS were evaluated in terms of hazard ratios (HRs) from Cox proportional hazards models stratified by cohort. 10-year DRFS was estimated for EPclin high-risk and low-risk women by Kaplan-Meier analysis. Results: Out of 411 eligible cases, 385 had a valid EPclin score and were included in the analysis. Mean age at breast cancer diagnosis was 46.5 years (standard deviation 4.7). Most women (N = 239, 62.6%) had grade II tumors and 16.1% (N = 62) had node-positive disease. Over the observation period (median 9.7 years, interquartile range 6.6-13.9 years), 35 women had a distant recurrence within 10 years. Both the molecular EP score and the molecular-clinicopathologic EPclin score were associated with increased risk of distant recurrence [HR 1.3, 95% confidence interval (CI) 1.2-1.5; p < 0.001 and HR 3.6, 95% CI 2.3-5.7; p < 0.001, respectively]. Of these patients, 249 (64.7%) were categorized as low risk by EPclin score while the remaining 136 (35.3%) were categorized as high risk. Compared to EPclin low-risk women, EPclin high-risk patients were more likely to experience distant recurrence (HR 4.6, 95% CI 1.4-15.2; p = 0.004). At 10 years post-diagnosis, EPclin low-risk women who received endocrine therapy alone had a DRFS of 97% (95% CI 93-99%). Conversely, EPclin high-risk women had a DRFS of only 76% (95% CI 67-82%). Conclusions: The EPclin score is highly associated with DRFS in pre-menopausal women who received adjuvant endocrine therapy alone. Based on these data, pre-menopausal women with EPclin low-risk breast cancer may safely forgo adjuvant chemotherapy in addition to endocrine therapy.